| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | -0.02 | 0.9 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |